Radiopharm Theranostics

We are developing a world-class platform of #radiopharmaceutical and #nuclearmedicine products for both diagnostic and #therapeutic uses. ASX: $RAD

[Radiopharm Theranostics @TeamRadiopharm]

New data from the ongoing Phase 1 HEAT trial evaluating 177Lu-RAD202, a first-in-class HER2-targeted radiopharmaceutical therapy, will be presented at the American Association for Cancer Research Annual Meeting, being held this week in San Diego: https://t.co/o3BMnZzhlq

[Radiopharm Theranostics @TeamRadiopharm]

We're pleased to share that the final patient has been dosed in the US Phase 2b imaging trial evaluating RAD 101 in individuals with confirmed recurrent brain metastases from solid tumors of different origin: https://t.co/WIAK96tV6C

[Radiopharm Theranostics @TeamRadiopharm]

We have received a positive recommendation from the DSMC to advance our clinical-stage radiotherapeutic asset, RAD202, to the next dose level of in the Phase 1 ‘HEAT’ clinical trial in patients with HER2-positive advanced solid tumors: https://t.co/F6L6mrCmpP

[Radiopharm Theranostics @TeamRadiopharm]

Today we announced the signing of a supply agreement in which Siemens Healthineers will radiolabel and distribute RAD101 with Fluorine-18: https://t.co/AUCiy4xvix

[Radiopharm Theranostics @TeamRadiopharm]

Today we shared that the first patient has been dosed in our first-in-human Phase 1 clinical trial of RAD 402, a monoclonal antibody targeting KLK3 radiolabelled with Terbium 161 being evaluated in advanced prostate cancer: https://t.co/18tW8pX39k

[Radiopharm Theranostics @TeamRadiopharm]

We are hosting a webinar on March 25 at 9:00 am AEDT (Sydney, Melbourne) / Tuesday, March 24 at 6:00 pm EST (U.S.) to discuss the second interim data.

Register at: https://t.co/7pvQdG1DS7

[Radiopharm Theranostics @TeamRadiopharm]

We're pleased to share the second interim data from 20 patients in our U.S. Phase 2b clinical imaging trial of RAD 101 in brain metastases: https://t.co/8JmdDQ92Zh

The analysis showed that 90% of the patients dosed with RAD101 achieved the primary endpoint.

[Radiopharm Theranostics @TeamRadiopharm]

We're pleased to share that CEO & Managing Director Riccardo Canevari will present at the @NWRComms Virtual Healthcare Conference on Wednesday, 25 March, at 8:30am AEDT.

Investors, shareholders, and interested parties are invited to register at: https://t.co/Kqg3r35IdG

[Radiopharm Theranostics @TeamRadiopharm]

The first patient has been dosed in our First-In-Human Phase 1/2a trial of 177Lu-Betabart: https://t.co/g6cVlWYoEK

The dose escalation & expansion trial is designed to evaluate its safety, biodistribution and radiation dosimetry, along with preliminary anti-tumor activity.

[Radiopharm Theranostics @TeamRadiopharm]

We are pleased to share an update from Brookline Capital Markets on $RAD following a fireside chat with CEO Riccardo Canevari.

Brookline maintains its Buy recommendation for the Company and a target price of $13 (NASDAQ)/$0.06 (ASX).

[Radiopharm Theranostics @TeamRadiopharm]

We have increased our ownership stake in Radiopharm Ventures, a joint venture created with The University of Texas MD Anderson Cancer Center, to 87.5%: https://t.co/w31jAoBSzc

The JV continues to show promising progress, including the advancement of its leading B7H3 candidate.

[Radiopharm Theranostics @TeamRadiopharm]

We are pleased to share an independent report on RAD released by Jones Research, who have reiterated its Buy rating and price target of $30 (NASDAQ) / $0.076 (ASX).

[Radiopharm Theranostics @TeamRadiopharm]

The Company will host a webinar tomorrow at 10am AEDT to discuss the data. Register at: https://t.co/F5qtNoN2xb

[Radiopharm Theranostics @TeamRadiopharm]

Today we announced interim data from the first twelve patients in our U.S. Phase 2b clinical imaging trial of RAD 101 in brain metastases: https://t.co/PNakGM8osB

The results showed significant and selective tumor uptake in the brain metastases.

[Radiopharm Theranostics @TeamRadiopharm]

We're pleased to announce the appointment of Mr Bruce Goodwin as a Non-Executive Director: https://t.co/fnumgaEuwl

Mr Goodwin is a highly respected leader in the life sciences sector, bringing over 4 decades of experience across global healthcare & biopharmaceutical industries.

[Radiopharm Theranostics @TeamRadiopharm]

We have been granted Bellberry Human Research Ethics Committee approval in Aust. to initiate our First-In-Human Phase 1 clinical trial of our KLK3-targeting radiotherapeutic, RAD 402, for the treatment of metastatic or locally advanced prostate cancer: https://t.co/AzeELT0Pty

[Radiopharm Theranostics @TeamRadiopharm]

Our Phase 2b trial evaluating RAD101 imaging in brain metastases has achieved 50% patient enrollment threshold: https://t.co/5ncrabWixV

Early patient data from Phase 2b clinical trial has shown significant and selective tumor uptake in brain metastases compared to MRI.

[Radiopharm Theranostics @TeamRadiopharm]

The first two Cohorts’ patients have shown tumor uptake and a favourable safety profile, with the Data Safety Monitoring Committee approving advancement to a higher dose of 90mCi.

[Radiopharm Theranostics @TeamRadiopharm]

We have completed enrollment for the 2nd cohort of patients in the Phase 1 dose escalation trial of 177Lu-RAD204 in PD-L1 positive advanced cancers: https://t.co/FXFTYnZfKG $RAD

[Radiopharm Theranostics @TeamRadiopharm]

We are pleased to share the latest report on $RAD released by Zacks Small-Cap Research, who have set a 12-month price target of $0.06 (ASX) / $13 (NASDAQ): https://t.co/AjOamQZFaV